Medicxi co-founder David Grainger gets his oth­er foot in Centes­sa's door as chief in­no­va­tion of­fi­cer

Centes­sa Phar­ma­ceu­ti­cals was built on the promise of scal­ing up Medicxi’s as­set-cen­tric mod­el with 10 of the VC firm’s port­fo­lio com­pa­nies and their in­di­vid­ual pro­grams un­der the same roof. But the crew wasn’t go­ing to stop there.

In­stead, now that the biotech has com­plet­ed its IPO, un­veiled the first batch of proof-of-con­cept da­ta from one of its 11 sub­sidiaries and — just a day ago — tapped in­to a fresh $300 mil­lion well of fi­nanc­ing, Centes­sa has set its sights on “strate­gic busi­ness de­vel­op­ment op­por­tu­ni­ties.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER